Cidara Therapeutics Inc [CDTX] stock prices are up 2.07% to $113.05 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CDTX shares have gain 10.84% over the last week, with a monthly amount glided 74.27%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Cidara Therapeutics Inc [NASDAQ: CDTX] stock has seen the most recent analyst activity on October 10, 2025, when JP Morgan initiated its Overweight rating and assigned the stock a price target of $200. On March 12, 2025, Citizens JMP initiated with a Mkt Outperform rating and assigned a price target of $46 on the stock. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $34 as its price target on December 13, 2024. Guggenheim started tracking with a Buy rating for this stock on November 08, 2024, and assigned it a price target of $33. In a note dated August 14, 2024, H.C. Wainwright upgraded a Buy rating on this stock but restated the target price of $24.
The stock price of Cidara Therapeutics Inc [CDTX] has been fluctuating between $10.14 and $111.35 over the past year. Currently, Wall Street analysts expect the stock to reach $156.75 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $113.05 at the most recent close of the market. An investor can expect a potential return of 38.66% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
The Cidara Therapeutics Inc [NASDAQ:CDTX] reported sales of 0.00M for trailing twelve months, representing a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.4 and Total Capital is -0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Cidara Therapeutics Inc [NASDAQ:CDTX]’s Current Ratio is 16.45. Further, the Quick Ratio stands at 16.45, while the Cash Ratio is 15.8.
Transactions by insiders
Recent insider trading involved Davarpanah Nicole Negar, Chief Medical Officer, that happened on Sep 11 ’25 when 474.0 shares were sold. Director, RA CAPITAL MANAGEMENT, L.P. completed a deal on Jun 26 ’25 to buy 2.27 million shares. Meanwhile, Director Mineo Chrysa bought 2270.0 shares on Jun 02 ’25.
